TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-na&#239;ve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations.

Datroway (datopotamab deruxtecan-dlnk) - Daiichi Sankyo, AstraZeneca

rilvegostomig (AZD2936) - AstraZeneca

Keytruda (pembrolizumab) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/41669261

Alessandra Forcina; Barbara Melosky; Giulia Pasello; Marta Stachowiak; Pavlo Lyfar; Rebecca S Heist; Shun Lu; Suresh S Ramalingam; Thomas Newsom-Davis; Xiwei Chen

Feb 11, 2026